Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Ins & Outs of Patient Assistance Programs

Samantha C. Shapiro, MD  |  March 3, 2022

  1. Apply online when available. Turnaround time is substantially quicker—weeks rather than months—for online applications than for mailed or faxed applications.
  2. Call the drug company directly with questions. PAP staff are responsive and great at troubleshooting. Calling is easier than finding answers on drug company websites, especially because PAP information is often buried beneath multiple clicks.
  3. Involve one of your team members to follow up with the patient and assist with the application process as needed. This is especially important for non-English-speaking patients because PAP phone services all start with prompts in English.
  4. Send in the provider part of the PAP application at the time of visit. Nearly all applications require a signed form from the prescriber as part of the application. These can be found on PAP websites.
  5. Encourage the patient to follow up with the drug company every two weeks to confirm receipt of all required documents and to check on status. Drugs won’t be approved if any part of the application is missing, but companies don’t typically notify patients about missing paperwork. Delays in approval notification are also common, and the patient typically needs to call to arrange delivery of the first shipment. It’s frustrating to find out a free drug supply has been approved for months, unbeknownst to the patient or provider.
  6. Remind the patient to call the drug company directly to set up refill deliveries. Some companies allow patients to sign up to receive text message reminders about refills.
  7. Plan ahead. Most drug companies approve free drug supplies for one year, although some may approve the drug for up to three years. If therapy is to be continued via a PAP, the patient must reapply one to three months before their approval lapses.

Figure 1. PAP phone numbers as of January 2022.

Patient Assistance Program

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Medications Phone number
My AbbVie Assist

adalimumab (Humira)

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

upadacitinib (Rinvoq)

risankizumab (Skyrizi)

(800) 222-6885
Amgen Safety Net Foundation

etanercept (Enbrel)

apremilast (Otezla)

(888) 762-6436
Pfizer PAP (Xelsource)

tofacitinib (Xeljanz)

(844) 935-5269
Novartis Patient Assistance Foundation

secukinumab (Cosentyx)

mycophenolate sodium (Myfortic)

canakinumab (Ilaris)

(800) 277-2254
J&J Patient Assistance Foundation

ustekinumab (Stelara)

guselkumab (Tremfya)

golimumab (Simponi)

infliximab (Remicade)

(800) 652-6227
Bristol Meyers Squibb Patient Assistance Foundation

abatacept (Orencia)

(800) 736-0003
Genentech Patient Foundation

tocilizumab (Actemra)

rituximab (Rituxan)

(888) 941-3331

Page: 1 2 3 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:biologic therapiesdrug costsfederally qualified health centerpatient assistance programs (PAP)patient careuninsured Americans

Related Articles

    Combine With Medicare Part D to Help Patients Afford Prescriptions

    February 1, 2007

    According to the 2003 U.S. Census, 29 million people in the United States make less than 200% of the federal poverty level and have no health insurance. Many persons have difficulty affording prescribed medications. In addition to Medicare Part D, there are more than 350 public and private patient assistance programs, including programs by pharmaceutical companies, that help patients pay for prescriptions.

    Colcrys Approval Triggers Questions

    May 1, 2010

    Some rheumatologists question the depth of research and the approval’s implications for patient access

    Drug Assistance Programs Offer Little Charity to Uninsured

    August 7, 2019

    (Reuters Health)—Many patients who receive assistance from charities set up to defray prescription drugs costs may already have insurance that covers most the cost for their medications, a U.S. study suggests. Researchers examined data on the six largest independent charities offering patient assistance programs through 274 different disease-specific programs. These programs had total revenue ranging…

    U.S. Uninsured Rate Up by Most in Nearly a Decade

    January 16, 2018

    WASHINGTON (Reuters)—The number of Americans without health insurance rose by 3.2 million people between 2016 and 2017, or 1.3% points to 12.2%, according to a Gallup poll released on Tuesday, the biggest jump in the uninsured rate in nearly a decade.1 Several factors likely contributed to the jump, Gallup said, including attempts by Republicans, who…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences